Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01250470 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma
A Phase 1 study, sponsored by Roswell Park Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT01250470 is a Phase 1 study that has completed, run by Roswell Park Cancer Institute. The registered enrollment target is 9 participants.
The verdict
NCT01250470, a Phase 1 study, has completed, sponsored by Roswell Park Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects of vaccine therapy when given together with sargramostim in treating patients with malignant glioma. Vaccines made from survivin peptide may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as sargramostim, may increase the number of white blood cells and platelets found in bone marrow or peripheral blood. Giving vaccine therapy and sargramostim may be a better treatment for malignant glioma.
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Sargramostim
- DRUG Montanide ISA-51/Survivin Peptide Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-09-05 |
| Est. Completion | 2014-05-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01250470
The ClinicalTrials.gov registry entry for NCT01250470 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01250470 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01250470 about?
NCT01250470 is a clinical study titled "Vaccine Therapy and Sargramostim in Treating Patients With Malignant Glioma". This phase I trial studies the side effects of vaccine therapy when given together with sargramostim in treating patients with malignant glioma. Vaccines made from survivin peptide may help the body build an effective immune response to kill tumor cells. Colony-stimulating factors, such as sargramos...
What is the current status of trial NCT01250470?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2012-09-05. Estimated completion is 2014-05-29.
What interventions are being tested in trial NCT01250470?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Sargramostim (BIOLOGICAL), Montanide ISA-51/Survivin Peptide Vaccine (DRUG).
Who is sponsoring clinical trial NCT01250470?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.